Mayo Clinic News Network

News Resources



Activity by mayonewsreleases


Aug 26, 2013 by mayonewsreleases · View  

Mayo Clinic: High-Tech Imaging Contributing To Overdiagnosis Of Low-Risk Thyroid Cancers

ROCHESTER, Minn. — Aug 26, 2013 — An increasing gap between the incidence of thyroid cancer and deaths from the disease suggests that low-risk cancers are being overdiagnosed and overtreated, a study from the
Mayo Clinic Center for the Science of Health Care Delivery finds. The study appears in the current issue of BMJ.

"High tech imaging technologies such as ultrasound, CT and MRI can detect very small thyroid nodules many of which are slow growing papillary thyroid cancers, says the study's lead author Juan Pablo Brito, M.B.B.S. an endocrine fellow and health care delivery scholar at Mayo Clinic. "This is exposing patients to unnecessary and harmful treatments that are inconsistent with their prognosis."


Click here to view the rest of the post

Login here to comment.

Aug 23, 2013 by mayonewsreleases · View  

Drug Used for Blood Cancers May Stop Spread of Breast Cancer Cells, Mayo Clinic Finds

MULTIMEDIA ALERT: For audio and video of Sahra Borges, Ph.D., talking about the study, visit the Mayo Clinic News Network.

JACKSONVILLE, Fla. — A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.

"Treatment with low doses of decitabine in an animal model of breast cancer restored PRKD1 expression, reduced tumor size, and blocked metastasis to the lung," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic in Florida.

"The outcome of patients with invasive breast cancer is less than optimal despite many attempts to improve treatment, including advanced chemotherapy and hormonal therapy," says Dr. Storz. "We hope this study offers a new avenue to prevent breast cancer from becoming aggressive and untreatable."

The research team, which includes first author Sahra Borges, Ph.D., a postdoctoral researcher in Dr. Storz's lab, found that the gene coding for PRKD1 was silenced in all but one subtype of invasive breast cancer, including aggressive triple negative breast cancer. That subtype is invasive lobular carcinoma.

Dr. Borges also developed an assay that can be used to measure the amount of PRKD1 that is silenced in patients' breast tumors.

"Because we found that PRKD1 is increasingly silenced as breast cancer becomes aggressive and spreads, the hope is that this test can be further developed and used to predict which patients are at risk for cancer metastasis, and thus may benefit from decitabine," Dr. Borges says.

Decitabine, approved by the U.S. Food and Drug Administration for use in some blood cancers, is a demethylating agent, meaning that it can switch on beneficial genes such as PRKD1 that cancer has silenced in order to grow.

Treating genes that are silenced is much easier than trying to restore function of a mutated gene, Dr. Storz says. The normal function of PRKD1, which is expressed in cells of the mammary gland, is to maintain normal function by preventing cells from morphing into a state where they can dislodge and spread, he says.

The researchers hope this study will help them to design a clinical trial in collaboration with Mayo Clinic physicians using decitabine to promote re-expression of PRKD1 and agents that activate PRKD1.

The study's other key researchers at Mayo include Heike Doeppler, Edith Perez, M.D., Cathy Andorfer, Ph.D., Zhifu Sun, M.D., Panos Anastasiadis, Ph.D., E. Aubrey Thompson, Ph.D., and Xochiquetzal J. Geiger, M.D. The study was supported by the National Institutes of Health (GM086435), the Bankhead-Coley Program of the Florida Department of Health, Mayo Clinic Breast Cancer SPORE, Breast Cancer Foundation, and from the 26.2 with Donna Foundation.

Login here to comment.

Aug 22, 2013 by mayonewsreleases · View  

Mayo Clinic to Open Stem Cell Laboratory in Phoenix

PHOENIX — Mayo Clinic in Arizona, with one of the most active bone marrow transplant programs in United States, will open its own stem cell laboratory in summer 2014. The laboratory will be initially dedicated to storing and processing stem cells used for bone marrow transplants at Mayo Clinic Hospital and Phoenix Children's Hospital.

Mayo Clinic is a regional referral center and performs more than 200 adult stem cell transplants each year and approximately 30 pediatric transplants with Phoenix Children's. The program is accredited by the Foundation for the Accreditation of Cellular Therapy and the National Bone Marrow Donor Program.

Stem cell (blood or marrow) transplant is the infusion or injection of healthy stem cells into the body to replace damaged or diseased stem cells. Although the procedure to replenish the body's supply of healthy blood-forming cells is generally called a stem cell transplant, it's also known as a bone marrow transplant, peripheral blood stem cell transplant or an umbilical cord blood transplant, depending on the source of the stem cells. Stem cell transplants can use cells from a person's own body (autologous stem cell transplant), from a donor (allogeneic stem cell transplant) or from an identical twin (syngeneic transplant).

Mayo Clinic's Bone Marrow Transplant program provides consultations, evaluations and treatment for patients who would potentially benefit from a stem cell transplant. Patients who are younger than age 18 are cared for through Mayo Clinic's pediatric program at Phoenix Children's Hospital.

The new 6,200-square-foot lab will be located on the Phoenix campus of Mayo Clinic in Arizona. Mayo Clinic physicians say the new lab will help increase capacity, improve turnaround times for processing and provide the potential for research-related activities including regenerative medicine.

Login here to comment.

Aug 21, 2013 by mayonewsreleases · View  

Mayo Clinic Offers New Intense Pulsed Light Therapy for Chronic Dry Eye

SCOTTSDALE, Ariz. – Intense Pulsed Light therapy (IPL) is being used at Mayo Clinic in Arizona to treat chronic dry eye, a condition affecting millions of people in the U.S., particularly those in the desert Southwest.

Video Alert::To view a video of Dr. Patel discussing the IPL therapy, visit the <ahref="">Mayo Clinic News Network


The standard treatment for chronic dry eye includes medications, daily eye drops and ointments to nourish the surface of the eye. In some cases, patients have been prescribed omega 3 fatty acid supplements and topical steroids. Left untreated, chronic dry eye can lead to impaired vision or scarring of the eye.

The IPL treatment targets patients who have evaporative dry eye, a subset of chronic dry eye. The condition results from ocular rosacea, inflammation of the eyelid skin, which causes the meibomian glands in the eyelids to fail to produce enough natural oil to slow the evaporation of tears. When that happens, patients experience a burning or gritty sensation, blurry vision and redness of the eyes.

The treatment provides relief for patients who have exhausted or failed to tolerate other treatment options such as drops, compresses or doxycycline pills.

IPL uses bursts of light directed at the lower eyelids and upper cheek areas that heat the eyelid glands that are blocked with stagnant secretions. The physician is then able to manually express the stagnant material from the eyelids.

Most patients require four monthly treatments to see full results, but many notice some transient improvement after a single treatment. For patients severely affected with evaporative dry eye, maintenance treatments are recommended every three to six months.

There are 30 centers around the U.S. offering this treatment, and now it is one of several in the arsenal of treatments for chronic dry eye at Mayo Clinic in Arizona.

Joanne Shen, M.D., and Dave Patel, M.D., Ophthalmology, who are fellowship-trained in ocular surface disease, treat patients with moderate to advanced dry eye.

Another treatment for dry eye at Mayo Clinic is LipiFlow. This system can evaluate the oil tear film thickness on the surface of the eye. If the patient is eligible, depending on the number of blocked meibomian glands, the LipiFlow treatment is used. Drs. Shen and Patel reserve this treatment for less inflamed dry eye patients.

In this treatment, a single-use eyepiece is placed over the eye that provides a controlled application of warmth and massage to the lids. Following the 12-minute massaging, the blocked oil glands are emptied, allowing for production of healthy oils that are critical for a healthy tear film.

"Patients with chronic dry eye experience more than inconvenience," says Dr. Shen. "The condition can impact their field of vision, can cause pain and can significantly impact their quality of life.

Causes of dry eye include side effects from medication, age, climate and excessive eye strain due to staring at a computer for long periods of time.

Some 5 million Americans are estimated to have chronic dry eye, and many others have been suffering but have not yet been diagnosed.

Login here to comment.

Aug 20, 2013 by mayonewsreleases · View  

Mayo Clinic Center for Individualized Medicine Helps Treat Complex Cancers, Solve Medical Mysteries


      For audio and video of Dr. Parker and the Carmichaels talking about the gift and individualized medicine, visit the

Mayo Clinic News Network


JACKSONVILLE, Fla. — You have a serious medical condition, but conventional tests fail to find an answer. You have no diagnosis and no effective treatment. What do you do? Mayo Clinic has always been a destination for patients seeking answers. Now, Mayo is taking that concept to the next level with the public launch of its Individualized Medicine Clinic at its Florida campus.

To help Mayo Clinic physicians and researchers usher in a new age of medicine that uses technologies like whole genome sequencing to find solutions for patients, Amelia Island, Fla., residents and philanthropists Cecilia and Dan Carmichael have donated $5 million to Mayo.

The Carmichaels learned about Mayo's work in individualized medicine after Cecilia Carmichael received treatment for breast cancer at Mayo's Florida campus.

"If our daughter or our granddaughters were to get cancer, hopefully it could be cured immediately and there would not be this thing hanging over them that any time it could come back," Cecilia Carmichael says.

"It's really an exciting time," Dan Carmichael says. "We want to support the Mayo staff that we've gotten to know and love in transforming care for our family and others."

The Mayo Clinic Individualized Medicine Clinic offers two types of consulting: one for cancer patients for whom standard treatments have failed, and one for "diagnostic odyssey" cases — complex or mysterious disorders that are difficult to diagnose, but appear to have a genetic cause.

"We are leveraging innovative genomic technologies so our physicians can understand a patient's disease at its most fundamental level and use that information to find answers specific to that patient's needs," says Alexander Parker, Ph.D., an epidemiologist and Florida-based associate director of the Mayo Clinic Center for Individualized Medicine.

A multidisciplinary team of experts will work closely with patients and their physicians to determine whether a patient is a good candidate for tests to identify genetic alterations that could help guide treatment. The team includes physicians trained in genomics, genomic scientists, genetic counselors, bioinformatics experts, laboratory professionals and bioethics representatives.

"We are very grateful for the Carmichaels' gift, which is accelerating the translation of genomics to patient care," Dr. Parker says. "Their generosity is helping us move from talking about the promise of genomic medicine to making it a reality for patients."

The Carmichaels' $5 million donation establishes the Cecilia and Dan Carmichael Family Associate Director for the Center of Individualized Medicine in Florida, as well as the Cecilia and Dan Carmichael Family Fund for Individualized Breast Cancer Medicine Honoring Edith Perez, M.D. The donation builds upon the Carmichael's previous generosity. In 2008, they established the Mayo Clinic Carmichael Family Endowed Fund for Individualized Breast Cancer Medicine and also provided funds for an assistant to Dr. Perez in the Breast Clinic at Mayo Clinic.

Mayo Clinic also has Individualized Medicine Clinics at its campuses in Rochester, Minn., and Arizona.

Login here to comment.

Aug 19, 2013 by mayonewsreleases · View  

Brain Cancer Survival Improved Following FDA Approval of Bevacizumab, Mayo Study Finds

ROCHESTER, Minn. — A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.

MULTIMEDIA ALERT: For audio and video resources, please visit the Mayo Clinic News Network.

"There has been a great deal of debate about the effectiveness of bevacizumab in treating patients with glioblastoma," says lead author Derek Johnson, M.D., a neuro-oncologist at Mayo Clinic Cancer Center. "Our study found that, at the population level, treatment strategies involving bevacizumab prolonged survival in patients with progressive glioblastoma."

Researchers analyzed data on 5,607 adult patients from the National Cancer Institute (NCI) Surveillance, Epidemiology and End Results (SEER) database before and after the conditional approval of bevacizumab for the treatment of glioblastoma in 2009. The SEER database covers 18 geographic areas of the U.S., which collectively represent 28 percent of the U.S. population.

Researchers studied survival in 1,715 patients with glioblastoma who died in 2006, 1,924 who died in 2008 and 1,968 who died in 2010. "The difference in survival between 2008 and 2010 was highly significant and likely unrelated to any advancements in supportive care," Dr. Johnson says. "This study provides the strongest evidence to date that bevacizumab therapy improves survival in patients with glioblastoma."

Glioblastoma, is an aggressive cancer in which tumors grow rapidly and spread rapidly to new sites. It is the most common malignant brain tumor in adults and accounts for about 22 percent of all brain cancers. About 3,000 people develop a glioblastoma each year in the U.S.

Co-authors include Heather Leeper, M.D., and Joon Uhm, M.D. both of Mayo Clinic.

About Mayo Clinic Cancer Center

As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call

Login here to comment.

Aug 15, 2013 by mayonewsreleases · View  

Mayo Clinic: Testes pré-clínicos podem levar a novo método de tratamento de linfoma do sistema nervoso central

JACKSONVILLE, Flórida — Uma droga aprovada recentemente para o tratamento de mieloma múltiplo está sendo testada para comprovar sua capacidade de combater o linfoma do sistema nervoso central (SNC), um câncer fatal do sistema imunológico, que pode afetar o cérebro, a medula e fluido espinhal e os olhos. O estudo clínico, que está em andamento nas três unidades da Clínica Mayo — na Flórida, Minnesota e Arizona — dá prosseguimento ao teste bem-sucedido da droga, a pomalidomida, em camundongos com linfoma do SNC. Os detalhes sobre o teste pré-clínico estão disponíveis no jornal científico PLOS ONE.

Aproximadamente 5.000 pacientes são diagnosticados com essa doença, todos os anos, nos Estados Unidos.

"Acreditamos que a pomalidomida pode beneficiar pacientes com esse tipo de câncer porque ela faz duas coisas que as demais drogas contra o câncer não fazem", diz o oncologista da Clínica Mayo de Jacksonville, na Flórida, Han Tun. "A droga tem uma excelente penetração no cérebro, o que é uma necessidade no tratamento de tumores cerebrais. O outro fator interessante é que essa droga, além de atacar diretamente as células do linfoma, também altera o microambiente do tumor", ele explica.

Han Tun é o principal pesquisador do estudo PLOS ONE e o principal pesquisador do estudo clínico, que está recrutando pacientes.

"Nosso estudo pré-clínico sugere que a pomalidomida é muito promissora. O tratamento com pomalidomida em camundongos contra o linfoma do SNC aumentou significativamente a sobrevivência e o crescimento do tumor", ele diz. "O estudo clínico de fase I foi desenvolvido com base nesses resultados pré-clínicos", diz o oncologista da Mayo.

A pomalidomida pertence à classe de drogas chamadas de agentes imunomoduladores. A talidomida foi a primeira droga dessa classe e foi aprovada em 2006 para o tratamento do mieloma múltiplo, um câncer da medula óssea. A pomalidomida foi aprovada para uso em mieloma múltiplo em fevereiro.

Entre os coautores do estudo estão cinco pesquisadores da Celgene, a fabricante da pomalidomida. Outros coautores são Zhimin Li, Ph.D.; Yushi Qiu, M.D.; Peng Huang, M.D., Ph.D.; David Personett; Brandy Edenfield; e John Copland, Ph.D., todos da Clínica Mayo da Flórida.

O oncologista Han Tun recebeu uma verba da Celgene em apoio à pesquisa.

Para mais informações sobre tratamento de mieloma múltiplo, linfoma do sistema nervoso central e outros tipos de câncer na Clínica Mayo de Jacksonville, Flórida, contate o departamento de Serviços Internacionais pelo telefone 904-953-7000 ou envie um email para

Login here to comment.

Aug 15, 2013 by mayonewsreleases · View  

Gaita ajuda pacientes de doenças pulmonares e transplantados a respirar melhor

JACKSONVILLE, Flórida — Depois de sobreviver a dois transplantes de pulmão, em 2005 e 2008, o músico Larry Rawdon compartilha uma nova forma de cura por música com outros pacientes da Clínica Mayo de Jacksonville, Flórida. Afinal, foi a música que o levou à Clínica Mayo e o ajudou a se recuperar, depois que foi diagnosticado, em 2002, com fibrose pulmonar idiopática.

Antes de chegar à Clínica Mayo, Rawdon tinha poucas esperanças de que sua doença iria melhorar. Mas um encontro casual com o cirurgião cardiotorácico Octavio E. Pajaro, M.D., durante um festival de música, em 2005, mudou seu ponto de vista sobre seu problema e trouxe esperança para Rawdon e sua família.

"Os instrumentos musicais sempre exerceram um impacto significativo em minha vida, que se estende além da própria música", diz Rawdon. "Foi o que realmente iniciou meu relacionamento com a Clínica Mayo e exerceu um papel importante nas mudanças em minha vida".

Amante de tudo que se refere à música, Rawdon se sentiu atraído por diversos instrumentos musicais. Sua carreira como violoncelista profissional o levou à Broadway e a experimentar um grande número de instrumentos. Assim, quando sua mulher Katie soube dos benefícios que tocar a gaita trazia para pacientes da medicina pulmonar, ela percebeu que havia encontrado o presente de Natal perfeito para seu marido.

"No Natal de 2007, ganhei duas gaitas de minha mulher e comecei, imediatamente, a me ensinar a tocar esse novo instrumento, observando outros músicos em vídeos no YouTube, conta Rawdon.

Sua paixão por compartilhar a gaita vem de sua experiência de reabilitação com ou sem esse instrumento.

Depois de seu segundo transplante de pulmão em 2008, Rawdon não perdeu tempo e pegou sua gaita para suplementar os exercícios prescritos de reabilitação pulmonar. Ele observou resultados significativamente positivos.

Rawdon notou que quando tocava a gaita por 10 minutos, durante exames de espirômetro de incentivo, as pontuações de capacidade pulmonar eram substancialmente elevadas, depois de tocar o instrumento.

Rawdon relatou seu êxito pessoal ao médico Cesar Keller, do Departamento de Serviços de Transplantes da Flórida.

"Pessoalmente, penso que essa técnica é um acréscimo e um complemento muito bom a todo o processo de recuperação geral de um transplante de pulmão", diz Cesar Keller. "Ela combina uma terapia respiratória excelente com a diversão e produz um resultado imediato, decorrente da execução do instrumento musical", ele explica.

O impacto profundo de tocar a gaita levou Rawdon a compartilhar seu amor pelo instrumento e por sua capacidade de reabilitação com outros pacientes no Grupo de Transplante do Coração e do Pulmão de Jacksonville. Em fevereiro, Rawdon começou a dar aulas de gaita aos demais pacientes, como um exercício de reabilitação pulmonar suplementar. As aulas são divertidas, envolventes e, além disso, trazem benefícios para os pacientes em processo de recuperação pulmonar.

"Estou convencido de que a gaita, para os pacientes de transplante de pulmão, pode ser considerado uma parte de um equipamento legítimo de exercício respiratório", diz Rawdon. "Além de tudo o mais que a gaita passou a representar para mim, é especialmente gratificante ouvir de outros pacientes de transplante que eles também estão se beneficiando o uso da gaita, pelo que estão percebendo".

Rawdon vem trabalhando diligentemente para ajudar a reunir recursos para desenvolver aulas de música de uma forma regular aos pacientes. Ele fez parceria com Chrys Yates, coordenadora do Centro para Humanidades em Medicina da Flórida, para ajudar a angariar suporte para a equipe da Clínica Mayo.

Ele contatou, por iniciativa própria, a Hohner Inc., uma grande fabricante de gaitas, para ajudar a fornecer o instrumento para os pacientes. Depois que Rawson contou sua história sobre a reabilitação com a ajuda da gaita ao presidente e associado de filantropia, a empresa se ofereceu para doar gaitas ao programa de Humanidades em Medicina, garantindo os instrumentos necessários para as aulas.

"A terapia respiratória é inestimável no processo de recuperação de pacientes de doenças pulmonares", explica Keller. "Depois de um transplante de pulmão, o caminho para uma recuperação completa depende, em grande medida, de o receptor do órgão conseguir recuperar sua capacidade funcional, após o processo debilitador de uma doença crônica e progressiva do pulmão. Isso é sempre complicado devido ao forte impacto fisiológico de uma grande cirurgia, como a de transplante de pulmão", ele diz. "Portanto, os papéis da terapia física, os exercícios para recuperar a resistência física e o vigor, bem como os exercícios de respiração para recuperar músculos diafragmáticos e respiratórios são fundamentais no processo de recuperação".

Para mais informações sobre tratamento da fibrose pulmonar idiopática e outras doenças respiratórias na Clínica Mayo de Jacksonville, Flórida, contate o departamento de Serviços Internacionais pelo telefone 904-953-7000 ou envie um email para

Login here to comment.

Aug 14, 2013 by mayonewsreleases · View  

Pesquisadores da Mayo Clinic decodificam origem do câncer de pâncreas causado por inflamação

JACKSONVILLE, Flórida — Pesquisadores da Clínica Mayo de Jacksonville, na Flórida, desvendaram o processo pelo qual uma inflamação crônica do pâncreas, a pancreatite, se transforma em câncer de pâncreas. Os cientistas informam que a descoberta revela formas de identificar pacientes de pancreatite com risco de contrair câncer de pâncreas, bem como a possíveis terapias medicamentosas que podem reverter o processo.

ALERTA DE VÍDEO: Para informações adicionais com áudio e vídeo com o Geou-Yarh Liou, Ph.D., acesse, Mayo Clinic News Network.

O estudo, publicado 5 de agosto no jornal online The Journal of Cell Biology, mapeia a forma com que a inflamação força células acinares no pâncreas — aquelas que produzem as enzimas digestivas — a se transformar em células ductais. Conforme essas células mudam, passam por mutações que podem resultar em maior progresso do câncer de pâncreas, diz o autor principal do estudo, o bioquímico e biólogo molecular da Clínica Mayo Peter Storz, Ph.D.

"Não sabemos porque essas células se reprogramam, mas pode ser porque produzir enzimas em um órgão danificado por uma inflamação pode causar mais danos", diz Peter Storz. "A boa notícia, entretanto, é que esse processo é reversível e nós identificamos uma quantidade de moléculas envolvidas nessa via, que podem ser o alvo no esforço para transformar essas novas células ductais de volta em células acinares, eliminando, com isso, o risco de desenvolvimento de câncer", ele explica.

Os cientistas estão testando a em ratos de laboratórios, a capacidade de medicamentos, já no mercado, de reverter essa transformação que ocorre no pâncreas que resulta em câncer de pâncreas humano. A equipe de pesquisa de Peter Storz traçou o trajeto que leva a inflamação no pâncreas ao desenvolvimento de câncer no órgão. Eles seguiram o que aconteceu, quando macrófagos responderam a um pâncreas inflamado. Macrófagos são um tipo de glóbulo branco que consome material estranho no organismo.

"A crença nesse campo tem sido a de que os macrófagos têm a função de remover células danificadas no órgão", diz Peter Storz. "Descobrimos que elas não são tão benignas assim. Percebemos que, na verdade, os próprios macrófagos provocam a transformação e criam a estrutura para o desenvolvimento do câncer", ele declara.

A equipe de pesquisa também descobriu que, quando o pâncreas está inflamado, o fluido do órgão contém moléculas sinalizadoras que induzem as células acinares a se transformarem em células ductais. Coautor do estudo, o gastrenterologista Massimo Raimondo, M.D., é integrante de uma equipe da Mayo que desenvolveu um método para coletar esse fluido do pâncreas durante uma esofagogastroduodenoscopia de rotina.

"Queremos investigar também se essas duas enzimas podem servir como um sistema de advertência precoce, um marcador do risco do câncer de pâncreas, em pacientes com pancreatite", diz Peter Storz. "Nossa esperança é de podermos detectar esse risco antes que ele se concretize e usar um tratamento que reverta qualquer possibilidade de desenvolvimento do câncer de pâncreas", ele explica.

O estudo foi financiado por verbas dos Institutos Nacionais de Saúde (CA135102, CA140182 e CA159222), pela Associação Americana da Pesquisa do Câncer e por uma verba dos Programas Especializados de Excelência em Pesquisa (SPORE — Specialized Programs for Research Excellence) da Clínica Mayo.

Entre os coautores do estudo estão Geou-Yarh Liou, Heike Doeppler, Brian Necela, Murli Krishna e Howard Crawford.

Para mais informações sobre tratamento do câncer de pâncreas e outros tipos de câncer na Clínica Mayo de Jacksonville, Flórida, contate o departamento de Serviços Internacionais pelo telefone 904-953-7000 ou envie um email para

Login here to comment.

Aug 12, 2013 by mayonewsreleases · View  

Mayo Clinic in Arizona Part of Study to Help Regulate Immune System

SCOTTSDALE, Ariz. — Researchers from Mayo Clinic and the University of Arizona are shedding light on a mechanism in the human body that may result in more effective treatments for conditions such as autoimmune disorders, cancer, allergies and chronic inflammation. The team has discovered a novel function of a protein previously believed to only help with blood clotting. The researchers found that this protein can prevent the immune system from going out of control – a condition that can ultimately harm the body.

The findings are published in the journal Immunity.

The protein is believed to work this way: When the body is attacked by viruses or bacteria, the immune system rallies to provide a defense mechanism. This is known as inflammation. While inflammation is needed to fight off viruses and other pathogens, it can also cause damage – and the immune system has to find the right balance so levels of inflammation are not too high or too low.

The question has always been, how does the immune system maintain that balance?

"Our discovery explains this," says co-author Sourav Ghosh, Ph.D., assistant professor in the Department of Cellular and Molecular Medicine at the UA College of Medicine in Tucson.

The researchers focused on two cells that control mediation of the body's immune response, with regulating inflammation the goal. They targeted specific immune responses in laboratory models to determine levels of inflammation and compared their findings with blood from patients with inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

The researchers found that patients experiencing increased inflammation had lower levels of a specific protein produced by cells than did healthy study participants.

The findings could result in more targeted treatments for the inflammatory bowel diseases, which can be especially promising because current treatment is limited at this time, and colon cancer is a significant risk for such patients, says co-author Jonathan Leighton, M.D., chair of Gastroenterology at Mayo Clinic in Arizona.

Dr. Leighton says, "From a clinical standpoint, we think that three factors predispose to inflammatory bowel disease – genetics, environment and the immune system. The immune system is a critical factor because it controls inflammation, and the results from our research provide insight on how to better control this inflammation."


The study was funded by the National Institutes of Health, the Crohn's and Colitis Foundation, the American Heart Association, the American Asthma Foundation, the Lupus Research Foundation and a Gershon-Trudeau Postdoctoral Fellowship.

Login here to comment.

Aug 12, 2013 by mayonewsreleases · View  

Mayo Clinic: Preclinical Tests May Lead to New Approach to Treat CNS Lymphoma

JACKSONVILLE, Fla. — A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic — in Florida, Minnesota and Arizona — follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma. Details of the preclinical testing are available in the science journal PLOS ONE.

Approximately 5,000 patients are diagnosed with the disease every year in the United States.

"We believe pomalidomide could be beneficial in patients with this cancer because it does two things that most anti-cancer drugs do not do," says Han Tun, M.D., an oncologist at Mayo Clinic in Florida. "The drug has excellent brain penetration, which is a requirement in treatment of brain tumors. The other interesting thing is that it is not only active directly against lymphoma cells but also alters the tumor microenvironment."

Dr. Tun is the senior investigator of the PLOS ONE study and the principal investigator for the clinical trial, which is accruing patients.

"Our preclinical study suggests pomalidomide is very promising. Treatment with pomalidomide in mouse models for CNS lymphoma significantly improved the survival and suppressed the tumor growth," he says. "The phase I clinical trial was developed based on these preclinical results."

Pomalidomide belongs to a class of drugs called immunomodulatory agents. Thalidomide was the first drug in this class and was approved in 2006 for treatment of multiple myeloma, a bone marrow cancer. Pomalidomide was approved for use in multiple myeloma in February.

Study co-authors include five researchers from Celgene, the manufacturer of pomalidomide. Other co-authors are Zhimin Li, Ph.D, Yushi Qiu, M.D., Peng Huang, M.D., Ph.D, David Personett, Brandy Edenfield, and John Copland, Ph.D., all from Mayo Clinic Florida.

Dr. Tun received a grant from Celgene to support this research.

Login here to comment.

Aug 12, 2013 by mayonewsreleases · View  

No Test to Diagnose Wheat or Gluten Sensitivity

ROCHESTER, Minn. — The August issue of Mayo Clinic Health Letter covers what's known — and not known — about wheat or gluten sensitivity.

For people with celiac disease or wheat allergy, avoiding wheat and gluten, a protein found in wheat, is critical to health. Gluten damages the inner lining of the small intestine and interferes with absorption of nutrients. Celiac disease can lead to anemia, osteoporosis, seizures, lymphoma or cancer of the small intestine.

Some people with annoying symptoms of irritable bowel syndrome including gas, bloating, constipation, diarrhea and abdominal discomfort, don't have celiac disease or a wheat allergy. Yet, they may see improvements in symptoms when they avoid wheat and gluten.

Doctors are reluctant to apply a definitive label to wheat sensitivity because it's not known exactly what causes symptoms. Wheat sensitivity symptoms also may include headaches, rashes, "brain fog," or fatigue. Gluten is usually blamed for wheat sensitivity. The thought is that there may be some type of immune reaction. And, other proteins or sugars in wheat could cause the symptoms.

So far, there's no diagnostic test for wheat sensitivity, other than eliminating wheat and gluten from the diet and reintroducing them to see if symptoms recur. Celiac disease can be diagnosed with blood tests and a biopsy of the small intestine.

A gluten-free diet doesn't hurt people who do not have celiac disease, as long as the diet remains well balanced. Sometimes a switch to a gluten-free diet reduces fiber intake, which can cause constipation, bloating and gas. On the plus side, gluten-free usually means cutting back on processed foods and eating more fresh fruits and vegetables.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online


jzlydaszyk responded Sun, Jul 12 at 7:28am EST · View

Is there information about the effectiveness of "gluten cutter", a Walgreens product?

Login here to comment.

Aug 12, 2013 by mayonewsreleases · View  

Thawing a Frozen Shoulder

ROCHESTER, Minn. — Worsening shoulder pain can be a sign of frozen shoulder (adhesive capsulitis). Whether treated or not, most cases of frozen shoulder improve on their own over the course of 12 to 18 months, according to the August issue of Mayo Clinic Health Letter.

The shoulder joint is made up of bones, ligaments and tendons. Surrounding the joint is the shoulder capsule, made up of strong connective tissue. Frozen shoulder occurs when the capsule thickens and tightens around the shoulder joint. Doctors don't know exactly what causes this change, which typically occurs slowly.

First, shoulder pain occurs with any movement and is usually worse at night. Pain increases and can be significant with or without movement. As a result, people tend to use the arm less, shoulder range of motion becomes more limited and the shoulder stiffens.

Next is the frozen stage. The shoulder pain diminishes especially when it's not used. The shoulder's range of motion decreases notably, and it becomes even stiffer. Activities such as combing hair or putting on a belt may be nearly impossible.

Finally, the shoulder thaws, the range of motion begins to improve but some pain may linger.

Without treatment, a frozen shoulder will eventually thaw, but full range of motion will likely not return. With relatively simple treatments, most people experience improvements.

Treatment typically includes nonprescription pain relievers to reduce pain and inflammation. If needed, stronger anti-inflammatory drugs could be used. Corticosteroid injections into the shoulder joint during the first stage may be of particular benefit for pain relief and may speed recovery.

Treatment also involves moving and stretching the shoulder to help prevent further loss of shoulder function. A physical therapist can help with exercises to maintain and regain as much shoulder mobility as possible. Some patients benefit from transcutaneous electrical nerve stimulation (TENS). This therapy delivers small electrical impulses through electrodes placed on the shoulders.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online.

Login here to comment.

Aug 12, 2013 by mayonewsreleases · View  

Most Neck Pain Improves with Self-care, Time

ROCHESTER, Minn. — Stiff neck or neck pain? For most patients, self-care and time are the best treatments.

The August issue of Mayo Clinic Health Letter covers neck pain, including common causes, self-care options and medical treatment. Neck pain can be mild to severe. It can be sharp or dull or cause neck stiffness. The pain may be just annoying or interfere with daily activities. But fortunately, neck pain isn't usually a sign of anything serious. And most people with common neck pain will experience a complete recovery in four to six weeks.

Common causes of neck pain are:

  • Muscle tension and strain: Too many hours hunched over a steering wheel, computer or workbench can cause muscle strain. Neck muscles also can tighten in response to problems such as arthritic joints of the spine.
  • Worn joints: There are seven vertebrae in the neck, which are connected by ligaments and joints. Just like any other joints, wear and tear can contribute to the development of arthritis.
  • Disk degeneration: With age, the spongy disks that cushion the vertebrae become stiff and provide less shock absorption. This can contribute to neck and upper back pain.

A doctor usually can't determine an exact cause of common neck pain, even with imaging tests. In most situations, the recommended treatment will be self-care to speed recovery. Components will likely include staying active, using good posture, and employing stress-reduction techniques such as deep breathing, meditation and progressive muscle relaxation. A heating pad, warm bath or gentle massage may ease symptoms. In the first few days, applying ice several times a day may relieve pain and reduce inflammation.

If pain doesn't diminish in four to six weeks, there are several treatment options to consider, including physical therapy and prescription medications to reduce pain, relax muscles or aid sleep. Trigger point needle injections may be helpful at the area of muscle tightness. These can be done with a needle only, with the injection of an anesthetic, or with an anesthetic and inflammation-suppressing corticosteroid. In addition, chiropractic manipulation has been shown to provide swift relief for neck pain. It's recommend that the manipulation not include quick, forceful motions. Rarely, this can cause damage to blood vessels that could lead to a stroke.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online.

Login here to comment.

Aug 8, 2013 by mayonewsreleases · View  

Mayo Clinic Announces Four Performances in September for the Rosemary and Meredith Willson Harmony for Mayo Program

ROCHESTER, Minn. — The public is invited to enjoy four Rosemary and Meredith Willson Harmony for Mayo Program concerts in September. Performances will be on Mondays from 12:10 to 1 p.m. in Barbara Woodward Lips Atrium, subway level, Rochester Methodist Hospital, Charlton Building, 10 Third Ave. NW.

The schedule is:

Sept. 9: Sowah Mensah will perform on African drums. Sowah is an ethnomusicologist, an accomplished composer and a "Master Drummer" from Ghana, West Africa. Sowah has taught music in both Ghana and Nigeria and is currently a music professor at Macalester College, the University of St. Thomas and the University of Vermont. Sowah is the director of Sankofa, a Ghanaian Folklore and Dance Ensemble in the Twin Cities and a member of Speaking in Tongues, a four-piece group based out of the Twin Cities that uses two percussionists, a bassist and a Chinese pipa player. Sowah's third solo album, Sii Sii Sii, was released in March 2007.

Sept. 16: Vicky Emerson will perform an Americana concert. This singer/songwriter from Wisconsin tours the country, offering audiences her unique blend of folk and blues and accomplished musicianship on piano and guitar. She has earned critical acclaim and numerous awards for her songwriting and released her fourth album, "Dust and Echoes," in 2012.

Sept. 23: Clay Ross and Rob Curto's band, Matuto, will perform Pan-American-influenced, folkloric rhythms. These Fulbright grant recipients mix Appalachian fiddle tunes with a Northeastern Brazilian lilt to create a unique blues riff. In May 2013 Matuto released their second full-length album, "The Devil and the Diamond" on Motéma Music.

Sept. 30: Buddy Mondlock, singer and songwriter, performs an Americana concert. This critically acclaimed songwriter has written for Garth Brooks, Nancy Wilcox and Joan Baez, among others. He tours the globe singing American folk and recently released "The Edge of the World," his most personal album to date.

Sponsored by Mayo Clinic Center for Humanities in Medicine, the Rosemary and Meredith Willson Harmony for Mayo Program is coordinated by the Choral Arts Ensemble of Rochester. The series is generously funded by the late Rosemary Willson in memory of her husband, Meredith Willson, who wrote the Broadway musical "The Music Man." The gift is made in gratitude for the couple's care at Mayo Clinic.

Login here to comment.

Aug 5, 2013 by mayonewsreleases · View  

Mayo Clinic in Arizona Completes 2,000th Kidney Transplant

PHOENIX — Mayo Clinic in Arizona has completed its 2,000th kidney transplant since the program opened in 1999 – a milestone that places the program among the 10 largest kidney transplant programs in the U.S. The 2,000th patient, a 24-year-old man from Arizona, received a kidney from a deceased donor and was recuperating well following the two-hour surgery at Mayo Clinic Hospital.

Of the 2,000 kidney transplants completed, nearly half were from living donors; a family member, friend, colleague or even an anonymous donor who agreed to donate a kidney. The donor's kidney is removed laparoscopically, a procedure in which surgeons place a thin tube with a camera into small incisions in the abdomen. This results in shorter waiting times for the recipient and significantly smaller incisions and less post-operative pain for the living donor.

Mayo Clinic was the first medical center in Arizona to perform a laparoscopic donor kidney removal.

Mayo Clinic also uses the paired kidney exchange program to increase the pool of available kidneys. In this process, a donor leads an exchange of organs among strangers who are a match. In the past, a patient who could not connect with a compatible living donor would have to wait for an organ from a deceased donor. The exchange program helps address the shortage of organs from deceased donors by finding a matching living donor for the patient. Since 2008, Mayo Clinic in Arizona has performed 41 kidney transplants through the paired kidney exchange program.

Mayo's kidney transplant program is successful because of a dedicated and integrated team of specialists "who put the patients above all else," says Raymond Heilman, M.D., chair of Nephrology at Mayo Clinic in Arizona. He also credits the living donors and families of deceased donors.

"Our work with Donor Network of Arizona is critical to the success of the program. It is their dedication and educational programs about the importance of organ donation that keeps the message in the mainstream," Dr. Heilman says. "More and more people are saying 'yes' to the generous and important gift of life."

Kunam Reddy, M.D., Transplant Surgery, Mayo Clinic in Arizona, lauded the transplant team for their success in reaching the 2,000th kidney milestone. "We can credit our skilled and dedicated team for having the vision and passion for serving so many patients with kidney failure. Our hope is that our success will motivate more people to make the decision to become organ donors and to save even more lives."

Mayo Clinic, through its campuses in Arizona, Florida and Minnesota, performs more transplants than anyone else in the U.S.

Nearly 97,000 people in the U.S. are awaiting a kidney transplant, including approximately 2,000 in Arizona.

Login here to comment.

Aug 5, 2013 by mayonewsreleases · View  

Mayo Clinic Researchers Decode Origin of Inflammation-Driven Pancreatic Cancer

JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida have revealed the process by which chronic inflammation of the pancreas, pancreatitis, morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies that might reverse the process.

MULTIMEDIA ALERT: For audio and video of Geou-Yarh Liou, Ph.D. discussing this study, visit the Mayo Clinic News Network.

The study, published online today in The Journal of Cell Biology, maps how inflammation pushes acinar cells in the pancreas — those that produce digestive enzymes — to transform into duct-like cells. As these cells change, they can acquire mutations that can result in further progression to pancreatic cancer, says senior author Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic.

"We don't know why these cells reprogram themselves, but it may be because producing enzymes in an organ that is injured due to inflammation may cause more damage," Dr. Storz says. "The good news, however, is that this process is reversible, and we identified a number of molecules involved in this pathway that might be targeted to help push these new duct-like cells back into acinar cells, thus eliminating the risk of cancer development."

The scientists are testing the ability of drugs already on the market to reverse this cellular transformation in the pancreas in mice models of human pancreatic cancer. Dr. Storz's research team traced the pathway leading from inflammation in the pancreas to development of cancer in the organ. They followed what happened once macrophages responded to an inflamed pancreas. Macrophages are a type of white blood cell that eats foreign material in the body.

"The belief in the field has been that macrophages were there to remove damaged cells in the organ," Dr. Storz says. "We found they weren't that benign. In fact, we discovered macrophages themselves drive the transformation and provide the setting for development of cancer."

The research team also discovered that if the pancreas is inflamed, fluid from the pancreas contains signaling molecules that induce acinar cells to transform into duct-like cells. Study co-author Massimo Raimondo, M.D., a gastroenterologist, is part of a Mayo team that has developed a method to collect this fluid from the pancreas during a routine upper endoscopy test.

"We want to also investigate whether these two enzymes can serve as an early warning system, a marker of pancreatic cancer risk, in patients with pancreatitis," Dr. Storz says.

"Our hope is that we can detect that risk before cancer happens, and use a treatment that reverses any possibility that pancreatic cancer will develop," he says.

The study was supported by National Institutes of Health grants (CA135102, CA140182 and CA159222), the American Association for Cancer Research, and a Mayo Clinic SPORE in Pancreatic Cancer grant.

Co-authors include Geou-Yarh Liou, Ph.D., Heike Doeppler, Brian Necela, Ph.D., Murli Krishna, M.D., and Howard Crawford, Ph.D.

About Mayo Clinic Cancer Center

As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.

Login here to comment.

Jul 24, 2013 by mayonewsreleases · View  

Enlarged Prostate — Many Options to Treat this Common Problem

ROCHESTER, Minn. — More than half of men in their 60s experience symptoms caused by an enlarged prostate gland. Add another decade or two, and nearly all men experience symptoms that may include a weak urine stream, difficulty starting urination, stopping and starting while urinating, and an urgent need to urinate.

The July issue of Mayo Clinic Health Letter covers how the prostate gland changes with age and ways to find relief for what's technically termed benign prostatic hyperplasia.

The prostate gland is just below the bladder and surrounds the urethra — through which urine passes out of the body. After puberty, the prostate gland is about the size of a walnut. As men age, the prostate gland can increase in size, pressing on the urethra and interfering with urine flow.

Men with mildly enlarged prostate glands and mild symptoms may not need immediate treatment. Studies have shown that up to one-third of mild cases clear up without treatment.

When treatment is needed, the focus is on reducing troubling symptoms and restoring normal urinary tract function. Several medication options are available for men with mild-to-moderate symptoms. Therapies include:

Alpha blockers: These drugs relax the bladder neck muscles and muscle fibers in the prostate. They help increase urine flow and reduce the need to urinate as often. Medications in this category are terazosin, doxazosin, tamsulosin, alfuzosin and silodosin.

Enzyme (5-alpha-reductase) inhibitors: These medications shrink prostate tissue and generally work best for very enlarged prostates. Medications include finasteride and dutasteride. Optimal improvement may take months.

Tadalafil: This medication for erectile dysfunction was recently approved for treating symptoms of prostate enlargement.

Surgery is an option when medications aren't effective or symptoms are moderate to severe. Some men prefer surgical repair to daily medication. The main surgeries remove prostate tissue that is blocking urine flow. Some procedures pose risks, including loss of bladder control and impotence.

Surgery options include:

Transurethral resection of the prostate: This procedure opens the channel through the prostate to relieve obstruction. Most men experience a stronger urine flow soon afterwards. A short hospital stay is often needed. Re-treatment may be needed in five to seven years.

Open prostate removal (simple prostatectomy): The interior portion of the prostate is removed either through an incision in the lower abdomen or through smaller openings using laparoscopic or robot-assisted surgery. Recovery requires several days in the hospital and use of a urinary catheter for one to two weeks.

Minimally invasive therapies: These procedures use different forms of heat or energy to shrink or remove excess prostate tissue around the urethra or to enlarge the opening from the bladder. At Mayo Clinic, these procedures are typically done on an outpatient basis. Symptoms generally improve right away and the risk of side effects is lower than when TURP is done.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online.

Login here to comment.

Jul 24, 2013 by mayonewsreleases · View  

Relief from Persistent Itching and Scratching

ROCHESTER, Minn. — There's no one-size-fits-all treatment for persistent itching. But there are effective therapies for most types of severe or persistent itching, according to the July issue of Mayo Clinic Health Letter.

Itching can have hundreds of possible causes. In general, there are skin problems that cause an itchy rash and internal problems that usually don't result in a rash. Itching with a rash could be the result of dry skin, allergic reactions, skin disorders, or infectious diseases such as chickenpox or shingles.

Treatments include:

Medications: Oral antihistamines ease itching due to allergies or hives. Corticosteroids help with itching caused by skin inflammation.

Wet dressings: Medicated cream is applied to the affected areas and covered by wet cotton cloths. This approach often is effective when other therapies fail.

Phototherapy: The skin is exposed to certain wavelengths of ultraviolet light several times a week over the course of weeks or months.

Itching that occurs without a rash can be the result of diseases (liver disease, kidney failure, anemia, some cancers and many other conditions), medications (narcotic pain relievers and some cancer medications) and nerve dysfunction (pinched or irritated nerves).

Treating the underlying condition or adjusting medications can provide relief. Antidepressants may be helpful in select situations where other therapies haven't worked.

Most types of itching respond well to treatment, but the relief may not be immediate. A number of topical creams and ointments can help relieve the itch immediately. Options include topical anesthetics such as lidocaine or benzocaine and ointments and lotions such as peppermint, camphor or calamine.

When itching persists, it's a good idea to check with a physician for a diagnosis and treatment. Persistent itching can lead to insomnia, anxiety, depression and diminished quality of life. Prolonged itching and scratching may increase the intensity of the itch, leading to lichen simplex chronicus, a condition where the skin becomes thick and leathery and more difficult to treat.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online.

Login here to comment.

Jul 24, 2013 by mayonewsreleases · View  

No Map for Grieving, and Sometimes Help is Needed

ROCHESTER, Minn. — Grieving the loss of a loved one can't be planned or mapped. At one time, the belief was that grief occurred in a set pattern of five stages. It's now known to be more complicated. The July issue of Mayo Clinic Health Letter covers common feelings and physical symptoms associated with grief, ways to cope, and signs that indicate help from a trained professional would be beneficial.

In the early days after a significant loss, many people say they feel numb. As numbness wears off, people often experience more intense and painful feelings of loss. Physical symptoms may arise that include upset stomach, loss of appetite, chest tightness, trouble sleeping, exhaustion and difficulty breathing. For weeks and months, waves of distress may occur that can include restlessness, anxiety and anger. In time, this normal process subsides and letting go begins.

Options to help cope with grief include:

Sharing the experience: Talking with a close friend or family member can be helpful.

Writing feelings down: Writing a letter to a deceased loved one or journaling are ways to share happy memories or regrets about what was never said.

Self-care: Daily physical activity, healthy foods, time with friends and physical pleasures — baths, massages or even naps — can ease distress.

Support groups: Sharing the grief experience reduces feelings of isolation and can be a source of practical advice.

Some people benefit from professional help as they grieve. An inability to stop thinking about the death and its circumstances is a signal that expert help is needed. A primary care doctor is a good place to start. Treatment might include medications to improve sleep and ease anxiety or referral to a counselor or therapist.

Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. To subscribe, please call 800-333-9037 (toll-free), extension 9771, or visit Mayo Clinic Health Letter Online.

Login here to comment.

Load More    

Loading information...